The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease

@article{Scheller2008TheIV,
  title={The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease},
  author={Dieter K A Scheller and Christoph Ullmer and Reinhard Berkels and Mirella Gwarek and Hermann Lübbert},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2008},
  volume={379},
  pages={73-86}
}
Rotigotine (Neupro®) is a non-ergoline dopamine agonist developed for the once daily treatment of Parkinson’s disease (PD) using a transdermal delivery system (patch) which provides patients with the drug continuously over 24 h. To fully understand the pharmacological actions of rotigotine, the present study determined its extended receptor profile. In standard binding assays, rotigotine demonstrated the highest affinity for dopamine receptors, particularly the dopamine D3 receptor (Ki = 0.71… 
Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease
TLDR
Transdermally delivered rotigotine is a clinically innovative and useful addition to the dopamine‐receptor agonist class and can improve early morning and nocturnal symptoms of Parkinson's disease.
Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome
TLDR
The constant transdermal delivery of rotigotine over 24 h is hypothesized to approximate continuous agonist–receptor stimulation, which conceptually more closely mimics physiologic striatal dopamine receptor function.
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
TLDR
In these post hoc analyses, adjunctive treatment with rotigotine in patients already receiving an MAO-B inhibitor improved UPDRS II+III score; this appeared to be largely driven by improvements in the motor aspects of PD.
An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
TLDR
Rotigotine was generally well tolerated, with an adverse event profile consistent with dopaminergic stimulation and use of a transdermal patch, and support the use of rotigotine as a continuous non-ergot D3/D2/D1 dopamine receptor agonist in the treatment of PD and RLS.
Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson’s disease
TLDR
Dermal administration of rotigotine in a rat model of PD could suppress an overactive bladder andIntercontraction interval (ICI) and voiding pressure (VP) were determined.
Neuroprotective effect of rotigotine against complex I inhibitors, MPP⁺ and rotenone, in primary mesencephalic cell culture.
TLDR
Rotigotine provides minor protection against MPP⁺ and rescues a significant number of THir neurons against rotenone in primary mesencephalic cell cultures relevant to PD.
Rotigotine Transdermal Patch: A Review in Parkinson’s Disease
TLDR
Rotigotine TP variously improved some non-motor symptoms of PD, in particular sleep disturbances and health-related quality of life (HRQOL), based on findings from individual studies and/or a meta-analysis.
...
...

References

SHOWING 1-10 OF 103 REFERENCES
Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.
TLDR
As the first full dopamine D 1 receptor agonist to show efficacy in PD patients and to reduce the craving and subjective effects of cocaine in cocaine abusers, adrogolide represents an important tool in understanding the pharmacotherapeutic potential of dopamine D1 receptor agonists.
Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
TLDR
Pramipexoles' demonstrated clinical efficacy for successful treatment in early disease for several years and as adjunctive therapy with L-dopa in late disease suggests a potential new paradigm for treatment of Parkinson's disease whereby new patients are initiated with pramipexole therapy and L-Dopa is added only as necessary.
Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease
  • M. Piercey
  • Biology, Psychology
    Clinical neuropharmacology
  • 1998
TLDR
Pramipexole's demonstrated clinical efficacy for successful treatment in early disease for several years and as adjunctive therapy with L-dopa in late disease suggests a potential new paradigm for treatment of Parkinson's disease whereby new patients are initiated with pramipexoles therapy and L-Dopa is added only as necessary.
Neuroprotective effects of D3 dopamine receptor agonists.
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
  • J. Joyce
  • Psychology, Medicine
    Pharmacology & therapeutics
  • 2001
N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum
TLDR
The hypothesis that the antiparkinsonian effect of dopamine receptor agonists is mediated by a more complex interactions with dopamine receptor subtypes than currently believed is supported.
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease
A controlled trial of rotigotine monotherapy in early Parkinson's disease.
  • Medicine, Psychology
    Archives of neurology
  • 2003
TLDR
Rotigotine can be safely administered once daily transdermally and improves parkinsonian signs in patients with early PD.
ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
TLDR
ABT‐431 is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease, and these preliminary findings suggest that it may exhibit a reduced tendency to provoke dyskinesia.
...
...